Citi initiated coverage of Nektar (NKTR) with a Buy rating and $102 price target Citi also opened a “positive 90-day catalyst watch” on Nektar ahead of the Phase 2b alopecia areata data expected in December. The firm believes data for rezpegaldesleukin in atopic dermatitis “look competitive” in crowded field. It sees an “asymmetrical upside” opportunity for the shares into the December readout.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics Announces Chief Legal Officer Departure
- Hold Rating Maintained Amid Uncertainty in Rezpeg Trial Outcomes and Ongoing Research
- Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment
- Nektar files automatic mixed securities shelf
- Nektar Therapeutics Reveals Promising Phase 2b Trial Results